Michael Morabito
Stock Analyst at Chardan Capital
(n/a)
# 4,482
Out of 4,884 analysts
11
Total ratings
9.09%
Success rate
-28.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Morabito
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Maintains: Buy | $79 → $81 | $51.77 | +56.46% | 2 | Mar 17, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $202 → $203 | $298.87 | -32.08% | 2 | Feb 26, 2021 | |
| DRRX DURECT | Maintains: Buy | $70 → $80 | $0.67 | +11,899.40% | 2 | Feb 3, 2021 | |
| ETNB 89bio | Maintains: Buy | $59 → $95 | $10.16 | +835.04% | 3 | Sep 15, 2020 | |
| VKTX Viking Therapeutics | Maintains: Buy | $15 → $20 | $28.19 | -29.05% | 2 | Aug 31, 2020 |
Akero Therapeutics
Mar 17, 2021
Maintains: Buy
Price Target: $79 → $81
Current: $51.77
Upside: +56.46%
Madrigal Pharmaceuticals
Feb 26, 2021
Maintains: Buy
Price Target: $202 → $203
Current: $298.87
Upside: -32.08%
DURECT
Feb 3, 2021
Maintains: Buy
Price Target: $70 → $80
Current: $0.67
Upside: +11,899.40%
89bio
Sep 15, 2020
Maintains: Buy
Price Target: $59 → $95
Current: $10.16
Upside: +835.04%
Viking Therapeutics
Aug 31, 2020
Maintains: Buy
Price Target: $15 → $20
Current: $28.19
Upside: -29.05%